Follow
Gert Kiss
Gert Kiss
Type6 Therapeutics
Verified email at type6tx.com
Title
Cited by
Cited by
Year
Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction
JB Siegel, A Zanghellini, HM Lovick, G Kiss, AR Lambert, JL St. Clair, ...
Science 329 (5989), 309-313, 2010
11152010
Computational enzyme design
G Kiss, N Çelebi‐Ölçüm, R Moretti, D Baker, KN Houk
Angewandte Chemie International Edition 52 (22), 5700-5725, 2013
5452013
Iterative approach to computational enzyme design
HK Privett, G Kiss, TM Lee, R Blomberg, RA Chica, LM Thomas, D Hilvert, ...
Proceedings of the National Academy of Sciences 109 (10), 3790-3795, 2012
3822012
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ...
Nature cell biology 20 (9), 1064-1073, 2018
3412018
Bridging the gaps in design methodologies by evolutionary optimization of the stability and proficiency of designed Kemp eliminase KE59
O Khersonsky, G Kiss, D Röthlisberger, O Dym, S Albeck, KN Houk, ...
Proceedings of the National Academy of Sciences 109 (26), 10358-10363, 2012
2572012
Optimization of the in-silico-designed kemp eliminase KE70 by computational design and directed evolution
O Khersonsky, D Röthlisberger, AM Wollacott, P Murphy, O Dym, S Albeck, ...
Journal of molecular biology 407 (3), 391-412, 2011
2012011
Computational design of catalytic dyads and oxyanion holes for ester hydrolysis
F Richter, R Blomberg, SD Khare, G Kiss, AP Kuzin, AJT Smith, J Gallaher, ...
Journal of the American Chemical Society 134 (39), 16197-16206, 2012
1892012
Evaluation and ranking of enzyme designs
G Kiss, D Röthlisberger, D Baker, KN Houk
Protein science 19 (9), 1760-1773, 2010
1412010
Discovery of a regioselectivity switch in nitrating P450s guided by molecular dynamics simulations and Markov models
SC Dodani, G Kiss, JKB Cahn, Y Su, VS Pande, FH Arnold
Nature chemistry 8 (5), 419-425, 2016
1342016
Computational design of enone-binding proteins with catalytic activity for the Morita–Baylis–Hillman reaction
S Bjelic, LG Nivón, N Çelebi-Ölçüm, G Kiss, CF Rosewall, ...
ACS chemical biology 8 (4), 749-757, 2013
1012013
Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations
CL Araya, C Cenik, JA Reuter, G Kiss, VS Pande, MP Snyder, ...
Nature genetics 48 (2), 117-125, 2016
962016
Towards simple kinetic models of functional dynamics for a kinase subfamily
MM Sultan, G Kiss, VS Pande
Nature chemistry 10 (9), 903-909, 2018
592018
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
BJ Lee, JA Boyer, GL Burnett, AP Thottumkara, N Tibrewal, SL Wilson, ...
Nature chemical biology 17 (10), 1065-1074, 2021
512021
Spiroligozymes for transesterifications: Design and relationship of structure to activity
M Kheirabadi, N Çelebi-Ölçüm, MFL Parker, Q Zhao, G Kiss, ...
Journal of the American Chemical Society 134 (44), 18345-18353, 2012
492012
Computerbasiertes Enzymdesign
G Kiss, N Çelebi‐Ölçüm, R Moretti, D Baker, KN Houk
Angewandte Chemie 125 (22), 5810-5836, 2013
332013
Understanding protein dynamics with L1-regularized reversible hidden Markov models
R McGibbon, B Ramsundar, M Sultan, G Kiss, V Pande
International Conference on Machine Learning, 1197-1205, 2014
292014
Automatic selection of order parameters in the analysis of large scale molecular dynamics simulations
MM Sultan, G Kiss, D Shukla, VS Pande
Journal of chemical theory and computation 10 (12), 5217-5223, 2014
282014
A06 tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
R Nichols, C Schulze, A Bermingham, T Choy, J Cregg, G Kiss, ...
Journal of Thoracic Oncology 15 (2), S13-S14, 2020
27*2020
Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors
GL Burnett, YC Yang, JB Aggen, J Pitzen, MK Gliedt, CM Semko, ...
Journal of medicinal chemistry 66 (1), 149-169, 2022
262022
Substituted pyrazolopyrazines, imidazopyrazines and [1, 2, 4] triazolopyrazines as allosteric SHP2 inhibitors
BR Blank, J Pitzen, G Wang, WS Won, C Tzitzilonis, JJ Li, ES Koltun, ...
US Patent 11,739,093, 2023
16*2023
The system can't perform the operation now. Try again later.
Articles 1–20